Want to see JP:4579 full AI Analyst Report?
4579 Stock Chart & Stats
¥1010.00
-¥6.00(-1.49%)
At close: 4:00 PM EST
¥1010.00
-¥6.00(-1.49%)
Day’s Range― - ―
52-Week Range¥438.00 - ¥1,465.00
Previous CloseN/A
Volume117.60K
Average Volume (3M)352.93K
Market Cap
¥12.62B
Enterprise Value¥10.30K
Total Cash (Recent Filing)¥4.49B
Total Debt (Recent Filing)¥2.79B
Price to Earnings (P/E)173.0
Beta1.09
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.96
Shares Outstanding24,458,673
10 Day Avg. Volume795,170
30 Day Avg. Volume352,926
Financial Highlights & Ratios
PEG Ratio-0.58
Price to Book (P/B)3.47
Price to Sales (P/S)6.01
P/FCF Ratio-56.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)48.4
Revenue Forecast (FY)¥4.59B
Bulls Say, Bears Say
Bulls Say
Asset-light Out-licensing/partnering ModelAn out-licensing/partnering business model reduces the need for large commercial-capex and shifts late-stage development and commercialization risk to partners. That structure creates durable revenue pathways (upfronts, milestones, royalties) and allows scalable R&D investment without building a commercial infrastructure.
High Gross And Positive EBITDA MarginsSustained high gross margins and a positive EBITDA margin indicate strong underlying value capture for the company's programs and efficient direct cost structure. Durable margin strength supports funding of R&D programs, makes partnerships more attractive, and cushions operating volatility over multi-year development cycles.
Moderate Leverage With Equity GrowthModerate debt levels combined with recent equity growth provide balance-sheet resilience and financing flexibility for multi-year clinical programs. This capital structure reduces near-term solvency risk while preserving capacity to raise partner-backed funding or take on targeted debt without immediate distress.
Bears Say
Inconsistent Operating And Free Cash FlowVolatile OCF/FCF and episodes of negative cash flow weaken the firm's ability to reliably self-fund clinical development. Over a multi-quarter horizon this increases dependence on milestone payments, equity raises, or partner financing, which can dilute shareholders or delay programs when cash is scarce.
Declining Revenue And Earnings VolatilityA declining top line and episodic losses reduce predictability of licensing milestones and royalty streams central to the business model. Persistent revenue weakness and earnings swings can impair partner negotiation leverage and make long-term cashflow forecasting and R&D prioritization more difficult.
Low ROE And Rising Debt Vs Earlier YearsLow ROE indicates the company has struggled to convert capital into attractive shareholder returns, while rising leverage versus prior years reduces financial flexibility. Over several quarters this combination can constrain investment choices and increase the cost of capital for future drug development.
RaQualia Pharma Inc. News
4579 FAQ
What was RaQualia Pharma Inc.’s price range in the past 12 months?
RaQualia Pharma Inc. lowest stock price was ¥438.00 and its highest was ¥1465.00 in the past 12 months.
What is RaQualia Pharma Inc.’s market cap?
RaQualia Pharma Inc.’s market cap is ¥12.62B.
When is RaQualia Pharma Inc.’s upcoming earnings report date?
RaQualia Pharma Inc.’s upcoming earnings report date is Nov 06, 2026 which is in 83 days.
How were RaQualia Pharma Inc.’s earnings last quarter?
RaQualia Pharma Inc. released its earnings results on Aug 14, 2026. The company reported -¥9.26 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is RaQualia Pharma Inc. overvalued?
According to Wall Street analysts RaQualia Pharma Inc.’s price is currently Overvalued.
Does RaQualia Pharma Inc. pay dividends?
RaQualia Pharma Inc. does not currently pay dividends.
What is RaQualia Pharma Inc.’s EPS estimate?
RaQualia Pharma Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RaQualia Pharma Inc. have?
RaQualia Pharma Inc. has 24,458,673 shares outstanding.
What happened to RaQualia Pharma Inc.’s price movement after its last earnings report?
RaQualia Pharma Inc. reported an EPS of -¥9.26 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.775%.
Which hedge fund is a major shareholder of RaQualia Pharma Inc.?
Currently, no hedge funds are holding shares in JP:4579
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
RaQualia Pharma Inc.
RaQualia Pharma Inc., established in 2008 and based in Nagoya, Japan, is a pharmaceutical company dedicated to the global research and development of innovative drug compounds. Its human therapeutic pipeline features several key candidates. Tegoprazan, designed to treat gastroesophageal reflux disease (GERD), is currently undergoing Phase 1 clinical trials in the United States. Grapiprant is in Phase II development in the U.S. and Phase I in China for pain management; it is also being investigated in Phase I studies in both the U.S. and China for its potential in cancer therapy. Beyond human medicines, RaQualia Pharma develops a range of veterinary products. These include grapiprant for managing osteoarthritis in dogs, a ghrelin receptor agonist aimed at addressing cancer-related anorexia/cachexia syndrome and constipation stemming from spinal cord injury, and ELURA, a medication for combating weight loss in cats suffering from chronic kidney disease. The company's extensive R&D pipeline also covers various other therapeutic areas. This includes a TRPM8 blocker for neuropathic pain, a motilin receptor agonist targeting gastrointestinal motility disorders such as gastroparesis, functional dyspepsia, and post-operative ileus, and a potassium-competitive acid blocker for GERD, which has successfully concluded Phase 1 clinical trials. Further early-stage developments encompass a 5-HT4 partial agonist for gastroparesis, functional dyspepsia, and chronic constipation; a 5-HT2B antagonist for irritable bowel syndrome with diarrhea; EP4 antagonists for canine pain management and, in separate Phase I trials, for cancer and general pain indications; a serotonin 5-HT2A and dopamine D2 receptor blocker for schizophrenia; a Cyclooxygenase-2 inhibitor (Phase I for pain); a CB2 agonist; a selective sodium channel blocker; a P2X7 receptor antagonist (Phase I for neuropathic pain); and a retinoic acid receptor alpha agonist. To further its research and development initiatives, RaQualia maintains strategic partnerships with Interprotein Corporation, ASKA Pharmaceutical Co., Ltd., and Epigeneron, Inc.